NCT06957223 - Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 6, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

Major Depressive Disorder (MDD)

Interventions

DRUG

Dextromethorphan-Bupropion

Participants will receive a fixed-dose combination of dextromethorphan-bupropion, dosed according to approved guidelines for major depressive disorder, administered orally for 6 weeks.

DRUG

SSRIs

Participants will receive an SSRI at standard therapeutic doses, administered orally for 6 weeks.

Trial Locations (2)

25770

Combined Military Hospital, Nowshera

Department of Psychiatry, Combined Military Hospital Nowshera, Nowshera

All Listed Sponsors

collaborator

CMH Nowshera

UNKNOWN

lead

Asad Ullah Jan

OTHER_GOV